The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis - PubMed (original) (raw)
. 2006 Oct;91(10):4037-42.
doi: 10.1210/jc.2006-0305. Epub 2006 Jul 25.
Corinne Fisher, Tobias E Larsson, Siobhan I Davis, Daniel L Koller, Michael J Cullen, Mohamad S Draman, Niamh Conlon, Alka Jain, Neal S Fedarko, Bhaskar Dasgupta, Kenneth E White
Affiliations
- PMID: 16868048
- DOI: 10.1210/jc.2006-0305
The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis
Holly J Garringer et al. J Clin Endocrinol Metab. 2006 Oct.
Abstract
Context: Familial tumoral calcinosis (TC) results from disruptions in phosphate metabolism and is characterized by high serum phosphate with normal or elevated 1,25 dihydroxyvitamin vitamin D concentrations and ectopic and vascular calcifications. Recessive loss-of-function mutations in UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) and fibroblast growth factor-23 (FGF23) result in TC.
Objective: The objective of the study was to determine the relationship between GALNT3 and FGF23 in familial TC.
Design, setting, and patients: We assessed the major biochemical defects and potential genes involved in patients with TC.
Intervention: Combination therapy consisted of the phosphate binder Sevelamer and the carbonic anhydrase inhibitor acetazolamide.
Results: We report a patient homozygous for a GALNT3 exon 1 deletion, which is predicted to truncate the encoded protein. This patient had high serum FGF23 concentrations when assessed with a C-terminal FGF23 ELISA but low-normal FGF23 levels when tested with an ELISA for intact FGF23 concentrations. Matrix extracellular phosphoglycoprotein has been identified as a possible regulator of phosphate homeostasis. Serum matrix extracellular phosphoglycoprotein levels, however, were normal in the family with GALNT3-TC and a kindred with TC carrying the FGF23 S71G mutation. The tumoral masses of the patient with GALNT3-TC completely resolved after combination therapy.
Conclusions: Our findings demonstrate that GALNT3 inactivation in patients with TC leads to inadequate production of biologically active FGF23 as the most likely cause of the hyperphosphatemic phenotype. Furthermore, combination therapy may be effective for reducing the tumoral burden associated with familial TC.
Similar articles
- Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Ichikawa S, Imel EA, Sorenson AH, Severe R, Knudson P, Harris GJ, Shaker JL, Econs MJ. Ichikawa S, et al. J Clin Endocrinol Metab. 2006 Nov;91(11):4472-5. doi: 10.1210/jc.2006-1247. Epub 2006 Aug 29. J Clin Endocrinol Metab. 2006. PMID: 16940445 - Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S, Guigonis V, Imel EA, Courouble M, Heissat S, Henley JD, Sorenson AH, Petit B, Lienhardt A, Econs MJ. Ichikawa S, et al. J Clin Endocrinol Metab. 2007 May;92(5):1943-7. doi: 10.1210/jc.2006-1825. Epub 2007 Feb 20. J Clin Endocrinol Metab. 2007. PMID: 17311862 - A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis.
Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE. Larsson T, et al. J Clin Endocrinol Metab. 2005 Apr;90(4):2424-7. doi: 10.1210/jc.2004-2238. Epub 2005 Feb 1. J Clin Endocrinol Metab. 2005. PMID: 15687325 - Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).
Farrow EG, Imel EA, White KE. Farrow EG, et al. Best Pract Res Clin Rheumatol. 2011 Oct;25(5):735-47. doi: 10.1016/j.berh.2011.10.020. Best Pract Res Clin Rheumatol. 2011. PMID: 22142751 Free PMC article. Review. - Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
Folsom LJ, Imel EA. Folsom LJ, et al. Curr Osteoporos Rep. 2015 Apr;13(2):78-87. doi: 10.1007/s11914-015-0254-3. Curr Osteoporos Rep. 2015. PMID: 25656441 Review.
Cited by
- A GALNT3 mutation causing Hyperphosphatemic familial Tumoral calcinosis.
Wu A, Yang B, Yu X. Wu A, et al. Mol Genet Metab Rep. 2024 Jul 31;40:101128. doi: 10.1016/j.ymgmr.2024.101128. eCollection 2024 Sep. Mol Genet Metab Rep. 2024. PMID: 39185017 Free PMC article. - Structural and molecular imaging-based characterization of soft tissue and vascular calcification in hyperphosphatemic familial tumoral calcinosis.
Sheppard AJ, Paravastu SS, Farhadi F, Donnelly E, Hartley IR, Gafni RI, Saboury B, Collins MT, Roszko KL. Sheppard AJ, et al. J Bone Miner Res. 2024 Sep 2;39(9):1327-1339. doi: 10.1093/jbmr/zjae115. J Bone Miner Res. 2024. PMID: 39046425 - Hyperphosphatemia With Normal Kidney Function Associated With Genetic Variants of GALNT3.
Schulz I, Kutscher A, Krall P, Carpio D, Ardiles L. Schulz I, et al. Kidney Int Rep. 2023 Oct 3;8(12):2838-2841. doi: 10.1016/j.ekir.2023.09.032. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106599 Free PMC article. No abstract available. - Fibroblast Growth Factor 23 Bone Regulation and Downstream Hormonal Activity.
Clinkenbeard E. Clinkenbeard E. Calcif Tissue Int. 2023 Jul;113(1):4-20. doi: 10.1007/s00223-023-01092-1. Epub 2023 Jun 12. Calcif Tissue Int. 2023. PMID: 37306735 Review. - Phosphate Homeostasis and Disorders of Phosphate Metabolism.
Perumal NL, Padidela R. Perumal NL, et al. Curr Pediatr Rev. 2024;20(4):412-425. doi: 10.2174/1573396319666221221121350. Curr Pediatr Rev. 2024. PMID: 36545737 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources